CIP2A (D1M3H) Rabbit Antibody

INQUIRY

CAT. NO.: AMA-0256

Target Information
UniProt ID	Q8TCG1

Product Details
Size	100 µL
Reactivity	Human
Host	Rabbit
Source/Isotype	Rabbit IgG
Storage	Store at -20°C. Do not aliquot the antibody.
Purification	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val342 of human CIP2A protein.

Usage
Application	WB, IP
Product Usage Information Dilution	Western Blotting (1:1000); Immunoprecipitation (1:100)
MW (Target)	90 kDa

Background
Protein phosphatase 2A (PP2A) is a trimeric protein phosphatase and tumor suppressor that regulates the phosphorylation status of a wide variety of phosphoproteins. PP2A targets include many that play a role in the maintenance and progression of cancer . The cancerous inhibitor of protein phosphatase 2A (CIP2A) is a single pass membrane protein that binds the PP2A catalytic subunit to inhibit PP2A phosphatase activity. CIP2A is normally expressed at low levels in normal cells and tissues, but is elevated in human malignancies where it is thought to be oncogenic. Research studies demonstrate aberrant CIP2A expression in multiple tumor types, including those derived from the head and neck, liver, colon, lung, osteosarcoma, pancreatic, breast, and myeloid cancers. This evidence suggests that CIP2A interacts with many proteins that may play a role in cancer maintenance and progression. Additional studies indicate that CIP2A inhibits PP2A-mediated dephosphorylation of the proto-oncogene Myc at Ser64, which stabilizes and prevents proteolytic degradation of the Myc transcription factor.

Background

Protein phosphatase 2A (PP2A) is a trimeric protein phosphatase and tumor suppressor that regulates the phosphorylation status of a wide variety of phosphoproteins. PP2A targets include many that play a role in the maintenance and progression of cancer . The cancerous inhibitor of protein phosphatase 2A (CIP2A) is a single pass membrane protein that binds the PP2A catalytic subunit to inhibit PP2A phosphatase activity. CIP2A is normally expressed at low levels in normal cells and tissues, but is elevated in human malignancies where it is thought to be oncogenic. Research studies demonstrate aberrant CIP2A expression in multiple tumor types, including those derived from the head and neck, liver, colon, lung, osteosarcoma, pancreatic, breast, and myeloid cancers. This evidence suggests that CIP2A interacts with many proteins that may play a role in cancer maintenance and progression. Additional studies indicate that CIP2A inhibits PP2A-mediated dephosphorylation of the proto-oncogene Myc at Ser64, which stabilizes and prevents proteolytic degradation of the Myc transcription factor.

Our customers have direct access to our experts and give timely feedback to any online inquiries. If you are interested in our products, please contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.